0.4997

4.35% -0.0227

Pre-market: .52 0.0203 +4.06%

Applied Therapeutics Inc (APLT)

Overview News Price History Option Chain Financials Discussions Forecast

Applied Therapeutics Inc stock is traded at $0.4997, with a volume of 1.16M. It is down -4.35% in the last 24 hours and down -15.69% over the past month. Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Previous Close:

$0.5224

Open:

$0.5141

24h Volume:

1.16M

Relative Volume:

0.23

Market Cap:

$58.14M

Revenue:

Net Income/Loss:

$-119.76M

P/E Ratio:

-0.3701

EPS:

-1.35

Net Cash Flow:

$-55.17M

1W Performance:

-0.34%

1M Performance:

-15.69%

6M Performance:

-89.78%

1Y Performance:

-91.82%

1-Day Range:

$0.4934

$0.5295

1-Week Range:

$0.49

$0.6099

52-Week Range:

$0.4556

$10.62

Applied Therapeutics Inc Stock (APLT) Company Profile

Name

Applied Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

212-220-9226

Address

545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY

Employee

Twitter

@Applied_Tx

Next Earnings Date

2025-03-14

Latest SEC Filings

APLT's Discussions on Twitter

Compare APLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLT Applied Therapeutics Inc	0.4997	58.14M	0	-119.76M	-55.17M	-1.35
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-02-24	Downgrade	UBS	Buy → Neutral
Nov-29-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-31-24	Initiated	William Blair	Outperform
Mar-26-24	Initiated	RBC Capital Mkts	Outperform
Feb-22-24	Initiated	Leerink Partners	Outperform
Jan-04-22	Downgrade	Barclays	Overweight → Equal Weight
Aug-27-21	Downgrade	Goldman	Neutral → Sell
Jun-25-21	Resumed	Goldman	Neutral
Oct-08-20	Initiated	Truist	Buy
Apr-22-20	Initiated	Goldman	Buy
Feb-27-20	Initiated	Barclays	Overweight
Jun-10-19	Initiated	Citigroup	Buy
Jun-10-19	Initiated	Cowen	Outperform
Jun-10-19	Initiated	Robert W. Baird	Outperform

View All

Applied Therapeutics Inc Stock (APLT) Latest News

Mar 13, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 13, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mar 13, 2025

Mar 12, 2025

APPLIED THERAPEUTICS Earnings Preview: Recent $APLT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 12, 2025

A look into Applied Therapeutics Inc (APLT)’s deeper side - SETE News

Mar 12, 2025

Mar 09, 2025